Fulcrum Therapeutics Inc - Asset Resilience Ratio
Fulcrum Therapeutics Inc (FULC) has an Asset Resilience Ratio of 71.47% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Fulcrum Therapeutics Inc (FULC) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Fulcrum Therapeutics Inc's Asset Resilience Ratio has changed over time. See FULC book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Fulcrum Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Fulcrum Therapeutics Inc (FULC) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $153.57 Million | 71.47% |
| Total Liquid Assets | $153.57 Million | 71.47% |
Asset Resilience Insights
- Very High Liquidity: Fulcrum Therapeutics Inc maintains exceptional liquid asset reserves at 71.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Fulcrum Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Fulcrum Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Fulcrum Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 70.12% | $182.81 Million | $260.72 Million | -11.63pp |
| 2023-12-31 | 81.75% | $210.66 Million | $257.69 Million | +7.71pp |
| 2022-12-31 | 74.03% | $167.82 Million | $226.69 Million | -3.73pp |
| 2021-12-31 | 77.77% | $182.75 Million | $235.00 Million | +34.65pp |
| 2020-12-31 | 43.11% | $55.86 Million | $129.58 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $85.77 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $4.34 Million | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more